相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prognostic Role of Vitamin D Status and Efficacy of Vitamin D Supplementation in Cancer Patients: A Systematic Review
Consuelo Buttigliero et al.
ONCOLOGIST (2011)
The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers
Marco Volante et al.
VIRCHOWS ARCHIV (2011)
Proteinuria and favourable clinical response in a patient receiving paclitaxel plus bevacizumab for metastatic breast cancer
N. Karachaliou et al.
ANNALS OF ONCOLOGY (2010)
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas
Nicola Fazio et al.
CANCER TREATMENT REVIEWS (2010)
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
Hassane Izzedine et al.
EUROPEAN JOURNAL OF CANCER (2010)
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
M. Scartozzi et al.
ANNALS OF ONCOLOGY (2009)
Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network
Maria P. Brizzi et al.
BMC CANCER (2009)
Vitamin D, Proteinuria, Diabetic Nephropathy, and Progression of CKD
Rajiv Agarwal
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
Silvia Dellapasqua et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gastroenteropancreatic neuroendocrine tumours
Irvin M. Modlin et al.
LANCET ONCOLOGY (2008)
Vitamin D deficiency
Michael F. Holick
NEW ENGLAND JOURNAL OF MEDICINE (2007)
25-hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III)
Ian H. de Boer et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
TNM staging of foregut (neuro)endocrine tumors:: a consensus proposal including a grading system
G. Rindi et al.
VIRCHOWS ARCHIV (2006)
The anti-angiogenic basis of metronomic chemotherapy
RS Kerbel et al.
NATURE REVIEWS CANCER (2004)
分享论文
